Guardian Pharmacy Services, Inc. (NYSE:GRDN) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Guardian Pharmacy Services, Inc. has received a consensus rating of "Moderate Buy," with one sell rating and four buy ratings from analysts covering the stock.
• The average 1-year price target for the stock is $27.25, with Oppenheimer recently setting a target of $30.00 and maintaining an "outperform" rating.
• Large investors have recently increased their stakes in the company, with TimesSquare Capital Management purchasing approximately $17.35 million in shares during the second quarter.

Shares of Guardian Pharmacy Services, Inc. (NYSE:GRDN - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the five analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $27.25.

GRDN has been the topic of several analyst reports. Truist Financial lifted their target price on Guardian Pharmacy Services from $28.00 to $30.00 and gave the company a "buy" rating in a research report on Friday, September 26th. Weiss Ratings reiterated a "sell (d+)" rating on shares of Guardian Pharmacy Services in a research note on Wednesday. Wall Street Zen cut shares of Guardian Pharmacy Services from a "strong-buy" rating to a "buy" rating in a research note on Friday, October 3rd. Finally, Oppenheimer set a $30.00 price target on shares of Guardian Pharmacy Services and gave the stock an "outperform" rating in a research report on Friday.

Guardian Pharmacy Services Trading Down 0.1%

GRDN opened at $23.68 on Friday. The company's 50 day moving average is $25.27 and its 200 day moving average is $23.09. The company has a market cap of $1.50 billion and a price-to-earnings ratio of -15.58. Guardian Pharmacy Services has a 12-month low of $16.50 and a 12-month high of $30.39.

Hedge Funds Weigh In On Guardian Pharmacy Services

Large investors have recently made changes to their positions in the business. TimesSquare Capital Management LLC purchased a new stake in shares of Guardian Pharmacy Services during the second quarter worth about $17,351,000. Franklin Resources Inc. grew its holdings in Guardian Pharmacy Services by 32.2% during the 2nd quarter. Franklin Resources Inc. now owns 976,207 shares of the company's stock valued at $20,803,000 after buying an additional 237,630 shares in the last quarter. Boston Partners bought a new stake in shares of Guardian Pharmacy Services during the second quarter valued at approximately $4,227,000. Geode Capital Management LLC lifted its holdings in shares of Guardian Pharmacy Services by 65.9% in the second quarter. Geode Capital Management LLC now owns 336,701 shares of the company's stock worth $7,177,000 after buying an additional 133,715 shares in the last quarter. Finally, Sei Investments Co. boosted its position in shares of Guardian Pharmacy Services by 227.2% during the second quarter. Sei Investments Co. now owns 181,481 shares of the company's stock worth $3,867,000 after acquiring an additional 126,008 shares during the last quarter.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.